Skip to main content

Table 1 Demographic and Baseline Characteristics Across Patient Subgroups

From: Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

Characteristic

Patients with EM

(n = 416)

Patients with CM

(n = 587)

Patients with MO

(n = 220)

Patients with MDD

(n = 134)

Patients with GAD

(n = 120)

Prior CGRP exposure

(n = 98)

Age, years, mean (SD)

38.5 (12.2)

40.5 (12.5)

40.7 (12.4)

40.1 (10.6)

39.0 (11.7)

43.0 (12.2)

Sex, n (%)

 Female

301 (72.4)

459 (78.2)

155 (70.5)

110 (82.1)

99 (82.5)

77 (78.6)

 Male

115 (27.6)

126 (21.5)

65 (29.5)

24 (17.9)

21 (17.5)

21 (21.4)

 Other

0 (0.0)

2 (0.3)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Race, n (%)

 White

317 (76.2)

465 (79.2)

158 (71.8)

112 (83.6)

99 (82.5)

78 (79.6)

 Black or African American

59 (14.2)

78 (13.3)

42 (19.1)

14 (10.4)

11 (9.2)

11 (11.2)

 Asian

26 (6.3)

30 (5.1)

10 (4.5)

5 (3.7)

5 (4.2)

1 (1.0)

 Native American or American Indian

6 (1.4)

1 (0.2)

2 (0.9)

0 (0.0)

0 (0.0)

1 (1.0)

 Other

8 (1.9)

12 (2.0)

7 (3.2)

3 (2.2)

5 (4.2)

6 (6.1)

 Unknown

0 (0.0)

1 (0.2)

1 (0.5)

0 (0.0)

0 (0.0)

1 (1.0)

Duration of follow-up, months, mean (SD)

7.1 (4.4)

7.0 (4.5)

7.1 (3.7)

7.3 (4.4)

7.6 (4.5)

7.2 (4.7)

Baseline MMD, mean (SD)

10.0 (5.1)

14.7 (6.5)

13.4 (6.7)

14.5 (6.1)

14.3 (6.3)

13.1 (6.2)

Baseline MHD, mean (SD)

10.7 (6.1)

16.4 (8.3)

15.8 (8.8)

17.5 (8.0)

16.7 (8.3)

14.6 (7.9)

Prior preventive treatment failures, n (%)

 0

34 (8.2)

26 (4.4)

1 (0.5)

4 (3.0)

3 (2.5)

1 (1.0)

 1

54 (13.0)

57 (9.7)

12 (5.5)

11 (8.2)

9 (7.5)

9 (9.2)

 2

120 (28.8)

126 (21.5)

36 (16.4)

20 (14.9)

18 (15.0)

17 (17.3)

 3

105 (25.2)

177 (30.2)

62 (28.2)

42 (31.3)

39 (32.5)

17 (17.3)

 4

52 (12.5)

109 (18.6)

45 (20.5)

22 (16.4)

20 (16.7)

14 (14.3)

 5

18 (4.3)

38 (6.5)

26 (11.8)

12 (9.0)

10 (8.3)

12 (12.2)

  ≥ 6

33 (7.9)

54 (9.2)

38 (17.3)

23 (17.2)

21 (17.5)

28 (28.6)

Common baseline comorbid conditions, n (%)a

 Insomnia

64 (15.4)

132 (22.5)

65 (29.5)

49 (36.6)

42 (35.0)

27 (27.6)

 Allergies

63 (15.1)

95 (16.2)

38 (17.3)

30 (22.4)

24 (20.0)

19 (19.4)

 Neck pain

60 (14.4)

95 (16.2)

51 (23.2)

26 (19.4)

29 (24.2)

28 (28.6)

 Hypertension

61 (14.7)

82 (14.0)

32 (14.5)

26 (19.4)

22 (18.3)

18 (18.4)

 Back pain

46 (11.1)

92 (15.7)

35 (15.9)

20 (14.9)

24 (20.0)

20 (20.4)

 Obesity

47 (11.3)

90 (15.3)

38 (17.3)

37 (27.6)

27 (22.5)

20 (20.4)

 MDD

41 (9.9)

93 (15.8)

47 (21.4)

134 (100.0)

39 (32.5)

22 (22.4)

 GAD

27 (6.5)

93 (15.8)

52 (23.6)

39 (29.1)

120 (100.0)

22 (22.4)

 Chronic pain

32 (7.7)

79 (13.5)

41 (18.6)

26 (19.4)

34 (28.3)

22 (22.4)

 Asthma

38 (9.1)

63 (10.7)

33 (15.0)

18 (13.4)

20 (16.7)

13 (13.3)

Clinician-estimated adherence rate, mean (SD)

92.3 (17.6)

95.1 (13.1)

89.8 (19.7)

95.0 (12.3)

95.6 (10.0)

95.0 (11.2)

Patients with ≥ 80% adherence, n (%)

362 (87.0)

550 (93.7)

182 (82.7)

125 (93.3)

114 (95.0)

90 (91.8)

Discontinuation rate after fremanezumab index dose, n (%)

31 (7.5)

47 (8.0)

17 (7.7)

5 (3.7)

14 (11.7)

12 (12.2)

  1. CGRP, calcitonin gene-related peptide; CM, chronic migraine; EM, episodic migraine; GAD, generalized anxiety disorder; MDD, major depressive disorder; MHD, monthly headache days; MMD, monthly migraine days; MO, medication overuse; SD, standard deviation
  2. aIncidence ≥ 10% in the overall study population